embase.com — September 2026 traffic, keywords & AI visibility

embase.com draws an estimated 1,844 visits a month from search engines. Effectively all of it is organic — about 1,844 visits from unpaid results. Spread across 35 ranking keywords, that averages roughly 53 organic visits per keyword.

On our AI visibility scale embase.com earns 67 of 100 points, a grade C. It takes full marks for LLMS.txt and Structured data. The biggest gap is SEO health, at 0 of 20 points (0/100), worth 20 points if closed. It also loses points on Crawlability (0/10) and Company profile (22/25).

The llms.txt on embase.com runs to 81 lines (4,651 characters) across 12 sections, last generated in May 2026. It introduces the site as "Embase - Biomedical & Pharmacological Database". It tells AI engines the business works in Scientific Research Databases, Biomedical Literature and Pharmacology Intelligence. It describes 5 products, including Embase Premier, Embase Alerts and Drug Delivery Online. Services it lists include Custom Search Training, Literature Screening Support, Database Integration Consulting and Pharmacovigilance Analysis. The audience it names is Researchers, Academics, Pharma, Clinicians, aged 25-65 (Global). Technologies it mentions include HTTPS, Responsive Viewport, Search Engine and Database Indexing. The keywords it claims start with "Embase", "biomedical database", "pharmacology literature" and "Emtree thesaurus".

# Embase - Biomedical & Pharmacological Database

## About
Embase serves as the premier biomedical and pharmacological database, indexing over 32 million records from 8,500+ journals worldwide. It specializes in drug research, clinical trials, and medical device literature with unique Emtree indexing for precise searches. Researchers use it for systematic reviews, meta-analyses, and pharmacovigilance studies. The platform covers conference proceedings, regulatory documents, and non-English publications missed by competitors. Daily updates ensure access to the latest evidence. Pharma companies leverage Embase for drug safety monitoring and competitive intelligence. Academic institutions subscribe for comprehensive literature access. Its advanced filters and export tools integrate seamlessly with reference managers. Embase powers evidence-based medicine across clinical, regulatory, and policy domains. AI enhancements now speed up screening while maintaining expert curation standards. The service supports HTA submissions and Cochrane reviews globally. Users benefit from personalized alerts on specific therapies or diseases. With decades of refinement, Embase remains essential for high-quality research outputs. Its focus on pharmacology sets it apart in life sciences intelligence. Institutions value its role in grant applications and tenure dossiers. Embase bridges published scienc

Google lists embase.com for about 35 keywords, which together bring an estimated 1,844 organic visits a month.

The latest technical audit of embase.com scored 0 out of 100 overall. The audit makes 8 recommendations in all.

Embase's company profile names PubMed, Scopus, Web of Science and Google Scholar as competitors. Its own llms.txt adds clarivate.com/webofsciencegroup, scholar.google.com, clinicalkey.com and cochranelibrary.com. Outside its market, the domains ranked closest to it in our worldwide ranking are sweetdir.com, foottherapy.ir, ornskoldsvik.se and blazimg.com.

PubMed

Scopus

Web of Science

Google Scholar

clarivate.com/webofsciencegroup

scholar.google.com

clinicalkey.com

cochranelibrary.com